EGFR activation has been shown to interact with inflammatory pathways such as NF-κB and IL-6/STAT3, leading to enhanced tumor proliferation, angiogenesis, and an immunosuppressive microenvironment (9, 10). This evidence concerns the gene NFKB1 and neoplasm.